FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286297275> ?p ?o ?g. }

• W4286297275 endingPage "e21087" @default.
• W4286297275 startingPage "e21087" @default.
• W4286297275 abstract "e21087 Background: While laboratory parameters including PDL1 expression and NLR are associated with outcomes in patients with metastatic NSCLC treated with ICIs, these measures have not identified patients with rapid progression (RP) defined as progressive disease within 30 days. Clinical factors including patient age and weight loss have been associated with cancer outcomes in general. Identifying clinical correlates for NSCLC patients who experience RP on ICI therapy would be useful. Methods: The objective of this retrospective study was to evaluate relationships between pre-treatment cachexia and inflammation and RP in NSCLC patients who received 2nd- or 3rd- line single agent ICIs. Associations of age, race, gender, smoking status, and longitudinal changes in weight and NLR (from at least 6 weeks prior to treatment initiation) with RP were analyzed by univariate and multivariate statistical (Kaplan-Meier and related) methods. Results: 195 patients were included: 59% female, 18% Black, and 78% current or former smokers. 14% of patients had RP. Black race was associated with RP (HR = 2.32, p = 0.03). 191 patients had pretreatment weight available. 63% had weight loss prior to ICI, 25% with > 5% loss. Any weight loss and weight loss > 5% over the time period ≥6 weeks prior to treatment initiation were associated with RP (HR = 3.19 and 6.40, p = 0.03 and < 0.01). 188 patients had pretreatment NLR values, 63% and 42% had NLRs > 3.5 and > 5, respectively. Pre-treatment NLR > 5 and higher baseline NLR were associated with increased risk of RP (p = 0.03 and p < 0.01). In multivariate analysis adjusted by age, smoking status and weight change, higher pre-treatment NLR is found to differentially increase RP risk for black patients (interaction HR = 1.27, p = 0.03). A model with these 5 variables provided 84.5% AUC of ROC curve (80% sensitivity, 75% sensitivity) for prognosticating RP. Conclusions: This retrospective study identified clinical variables including pre-treatment NLR > 5, weight loss > 0% & > 5%, black race, smoking status, and age that were associated with RP in previously treated advanced NSCLC patients receiving single agent ICIs. Though this requires validation with racially diverse data sets, these clinical parameters may be useful in identifying patients at high risk of RP on 2 nd or 3 rd line ICI therapy. Future directions include evaluating clinical characteristics and laboratory parameters in NSCLC patients treated with ICIs combined with chemotherapy and novel immunotherapy regimens, as well as single agent ICIs in the first line setting. If these clinical characteristics are associated with frequent RP in the setting of first line ICI treatment, it would be reasonable to consider novel immune strategies in this patient subset." @default.
• W4286297275 created "2022-07-21" @default.
• W4286297275 creator A5008913834 @default.
• W4286297275 creator A5017312893 @default.
• W4286297275 creator A5024343309 @default.
• W4286297275 creator A5032871452 @default.
• W4286297275 creator A5040798556 @default.
• W4286297275 creator A5053344068 @default.
• W4286297275 creator A5069434595 @default.
• W4286297275 creator A5076710359 @default.
• W4286297275 date "2022-06-01" @default.
• W4286297275 modified "2023-09-26" @default.
• W4286297275 title "Clinical and laboratory parameters associated with rapid progression in advanced NSCLC patients treated with second or third-line single agent immune checkpoint inhibitors (ICIs)." @default.
• W4286297275 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e21087" @default.
• W4286297275 hasPublicationYear "2022" @default.
• W4286297275 type Work @default.
• W4286297275 citedByCount "0" @default.
• W4286297275 crossrefType "journal-article" @default.
• W4286297275 hasAuthorship W4286297275A5008913834 @default.
• W4286297275 hasAuthorship W4286297275A5017312893 @default.
• W4286297275 hasAuthorship W4286297275A5024343309 @default.
• W4286297275 hasAuthorship W4286297275A5032871452 @default.
• W4286297275 hasAuthorship W4286297275A5040798556 @default.
• W4286297275 hasAuthorship W4286297275A5053344068 @default.
• W4286297275 hasAuthorship W4286297275A5069434595 @default.
• W4286297275 hasAuthorship W4286297275A5076710359 @default.
• W4286297275 hasConcept C121608353 @default.
• W4286297275 hasConcept C126322002 @default.
• W4286297275 hasConcept C143998085 @default.
• W4286297275 hasConcept C144301174 @default.
• W4286297275 hasConcept C167135981 @default.
• W4286297275 hasConcept C2776907518 @default.
• W4286297275 hasConcept C2777704314 @default.
• W4286297275 hasConcept C2780739268 @default.
• W4286297275 hasConcept C3019894029 @default.
• W4286297275 hasConcept C38180746 @default.
• W4286297275 hasConcept C511355011 @default.
• W4286297275 hasConcept C544821477 @default.
• W4286297275 hasConcept C71924100 @default.
• W4286297275 hasConcept C90924648 @default.
• W4286297275 hasConceptScore W4286297275C121608353 @default.
• W4286297275 hasConceptScore W4286297275C126322002 @default.
• W4286297275 hasConceptScore W4286297275C143998085 @default.
• W4286297275 hasConceptScore W4286297275C144301174 @default.
• W4286297275 hasConceptScore W4286297275C167135981 @default.
• W4286297275 hasConceptScore W4286297275C2776907518 @default.
• W4286297275 hasConceptScore W4286297275C2777704314 @default.
• W4286297275 hasConceptScore W4286297275C2780739268 @default.
• W4286297275 hasConceptScore W4286297275C3019894029 @default.
• W4286297275 hasConceptScore W4286297275C38180746 @default.
• W4286297275 hasConceptScore W4286297275C511355011 @default.
• W4286297275 hasConceptScore W4286297275C544821477 @default.
• W4286297275 hasConceptScore W4286297275C71924100 @default.
• W4286297275 hasConceptScore W4286297275C90924648 @default.
• W4286297275 hasIssue "16_suppl" @default.
• W4286297275 hasLocation W42862972751 @default.
• W4286297275 hasOpenAccess W4286297275 @default.
• W4286297275 hasPrimaryLocation W42862972751 @default.
• W4286297275 hasRelatedWork W195067670 @default.
• W4286297275 hasRelatedWork W1998259048 @default.
• W4286297275 hasRelatedWork W2072795933 @default.
• W4286297275 hasRelatedWork W2109007021 @default.
• W4286297275 hasRelatedWork W2887214816 @default.
• W4286297275 hasRelatedWork W2887528069 @default.
• W4286297275 hasRelatedWork W3095421467 @default.
• W4286297275 hasRelatedWork W4235503789 @default.
• W4286297275 hasRelatedWork W4285006515 @default.
• W4286297275 hasRelatedWork W2612605095 @default.
• W4286297275 hasVolume "40" @default.
• W4286297275 isParatext "false" @default.
• W4286297275 isRetracted "false" @default.
• W4286297275 workType "article" @default.